CSPC Pharmaceutical Group Ltd (1093)

Currency in HKD
9.19
+0.23(+2.57%)
Closed·
1093 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
1093 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.879.21
52 wk Range
4.279.48
Key Statistics
Bid/Ask
9.18 / 9.19
Prev. Close
8.96
Open
8.97
Day's Range
8.87-9.21
52 wk Range
4.27-9.48
Volume
146.57M
Average Volume (3m)
205.69M
1-Year Change
48.59%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1093 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.90
Downside
-3.21%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 10 consecutive years
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

CSPC Pharmaceutical Group Ltd Company Profile

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People’s Republic of China.

Employees
21400
Market
Hong Kong

Compare 1093 to Peers and Sector

Metrics to compare
1093
Peers
Sector
Relationship
P/E Ratio
22.8x22.5x−0.5x
PEG Ratio
−0.78−1.050.00
Price/Book
3.0x2.2x2.6x
Price / LTM Sales
3.5x3.1x3.2x
Upside (Analyst Target)
3.4%3.5%43.8%
Fair Value Upside
Unlock3.7%5.1%Unlock

Analyst Ratings

21 Buy
4 Hold
3 Sell
Ratings:
28 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8.90
(-3.21% Downside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.36%
Dividend Yield
2.90%
Industry Median 2.48%
Annualised payout
0.26
Paid annually
5-Years Growth
+20.85%
Growth Streak

Earnings

Latest Release
May 29, 2025
EPS / Forecast
0.1291 / 0.15
Revenue / Forecast
7.01B / 7.28B
EPS Revisions
Last 90 days

1093 Income Statement

People Also Watch

89.05
1801
-0.06%
127.30
3690
+1.43%
47.10
0981
+1.73%

FAQ

What Stock Exchange Does CSPC Pharma Trade On?

CSPC Pharma is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for CSPC Pharma?

The stock symbol for CSPC Pharma is "1093."

What Is the CSPC Pharma Market Cap?

As of today, CSPC Pharma market cap is 104.58B.

What Is CSPC Pharma's Earnings Per Share (TTM)?

The CSPC Pharma EPS (TTM) is 0.36.

When Is the Next CSPC Pharma Earnings Date?

CSPC Pharma will release its next earnings report on 19 Aug 2025.

From a Technical Analysis Perspective, Is 1093 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has CSPC Pharma Stock Split?

CSPC Pharma has split 2 times.

How Many Employees Does CSPC Pharma Have?

CSPC Pharma has 21400 employees.

What is the current trading status of CSPC Pharma (1093)?

As of 18 Jul 2025, CSPC Pharma (1093) is trading at a price of 9.19, with a previous close of 8.96. The stock has fluctuated within a day range of 8.87 to 9.21, while its 52-week range spans from 4.27 to 9.48.

What Is CSPC Pharma (1093) Price Target According to Analysts?

The average 12-month price target for CSPC Pharma is HKD8.89518, with a high estimate of HKD13.8 and a low estimate of HKD5. 21 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Buy. The stock has an -3.21% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.